Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

National trends in prescription drug expenditures and projections for 2026.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same author

National trends in prescription drug expenditures and projections for 2025.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2025
Same author

A mixed-methods study assessing the performance of a clinical decision support tool for <i>Clostridioides difficile</i> testing for patients receiving laxatives.

Infection control and hospital epidemiology·2025
Same author

Antimicrobial Shortages: A Global Issue Impacting Infectious Diseases.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2024
Same author

National trends in prescription drug expenditures and projections for 2024.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2024
Same author

The expanding universe of gene and cell therapy.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2023
Same journal

Filtered or Fried? Rethinking Intraoperative Cell Salvage in Liver Transplantation.

Transplantation·2026
Same journal

Simultaneous Liver-kidney Versus Liver Transplantation Categorized by Pretransplant eGFR: Impact of the 2017 OPTN Policy.

Transplantation·2026
Same journal

Preformed Anti-DQ Alpha Donor-specific Antibodies and the Risk of Antibody-mediated Rejection After Kidney Transplantation.

Transplantation·2026
Same journal

People in Transplantation: Professor Nadey Hakim, MD, PhD, FRCS, FRCSGlas (Hon), FACS, President-Elect of The Transplantation Society.

Transplantation·2026
Same journal

IL-1 Receptor Blockade Modulates Inflammation During Sequential Perfusion in Ex Vivo Porcine Kidneys.

Transplantation·2026
Same journal

Regulatory T Cells Allosensitized Under the Blockade of CD80/CD86-CD28 Costimulation Prolonged Islet Allograft Survival.

Transplantation·2026
See all related articles

Related Experiment Video

Updated: May 30, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

A multicenter experience with generic tacrolimus conversion.

Lisa M McDevitt-Potter1, Basma Sadaka, Eric M Tichy

  • 1Department of Pharmacy and Division of Transplant Surgery, Tufts Medical Center, Boston, MA 02111, USA. lmcdevitt@tuftsmedicalcenter.org

Transplantation
|July 27, 2011
PubMed
Summary
This summary is machine-generated.

Switching to generic tacrolimus is safe and cost-effective for transplant recipients. While dose adjustments are sometimes needed, generic tacrolimus offers significant savings for patients and healthcare systems.

More Related Videos

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
06:08

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Published on: March 11, 2017

Related Experiment Videos

Last Updated: May 30, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
06:08

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Published on: March 11, 2017

Area of Science:

  • Pharmacoeconomics
  • Transplantation Medicine
  • Nephrology

Background:

  • The first generic tacrolimus became available in August 2009.
  • This study evaluated dose adjustments and cost savings associated with switching to generic tacrolimus.

Purpose of the Study:

  • To assess the clinical necessity of dose titrations after switching from brand-name to generic tacrolimus.
  • To quantify the drug cost savings achieved through generic tacrolimus substitution.

Main Methods:

  • A prospective, observational trial involving transplant recipients on stable tacrolimus doses.
  • Patients were converted from brand-name to generic tacrolimus on a milligram-to-milligram basis.
  • Data were collected pre- and post-conversion, with a control arm assessed 6 months prior to conversion.

Main Results:

  • Seventy conversions were analyzed across kidney, liver, and multiorgan transplant recipients.
  • Tacrolimus doses and trough concentrations remained similar between brand and generic forms.
  • Dose titrations were required in 21% of patients switching to generic tacrolimus, compared to 7% in the control arm (P=0.028).
  • Significant cost savings were observed, with mean monthly drug costs decreasing from $645 (brand) to $593 (generic).
  • Patient copays reduced from $38 (brand) to $15 (generic) monthly.

Conclusions:

  • Generic tacrolimus demonstrates similar dose requirements and trough levels compared to the brand-name formulation.
  • Generic substitution leads to substantial cost savings for both the healthcare system and patients.
  • Close post-conversion monitoring is recommended as some patients may necessitate dose adjustments.